Background: Rho(D) immune globulin (RhIg) is used to reduce RhD alloimmunization in pregnancy. This study describes potential causes for RhD alloimmunization after the development and implementation of RhIg.
Study Design And Methods: This retrospective descriptive study investigated RhD-negative patients born in 1965-2005 with anti-D newly identified during 2018-2022.
Background: Transfusion-transmissible infection (TTI) prevalence among US blood donors has been widely documented. Here we estimate the prevalence of donors presenting with ≥2 TTIs (multiple infections past or present referred to as coinfections) and describe their demographics and associations.
Methods: Data from the Transfusion-Transmissible Infections Monitoring System were compiled for October 2020-September 2023 (3 years).
Background: The Mirasol® Pathogen Reduction Technology System was developed to reduce transfusion-transmitted diseases in platelet (PLT) products.
Study Design And Methods: MiPLATE trial was a prospective, multicenter, controlled, randomized, non-inferiority (NI) study of the clinical effectiveness of conventional versus Mirasol-treated Apheresis PLTs in participants with hypoproliferative thrombocytopenia. The novel primary endpoint was days of ≥Grade 2 bleeding with an NI margin of 1.
Background: Blood center organizations (BCOs) have traditionally offered two gender choices (male or female) on the donor history questionnaire (DHQ). Our BCO was one of the first in the United States to offer additional options on our DHQ to improve the experience for gender nonconforming donors.
Study Design And Methods: Three years of data were analyzed from all blood donation visits between March 2019 and March 2022.